It is now well-established that the spike protein factories created by the experimental mRNA treatment intended to mitigate the effects of infection with the Wuhan Coronavirus do not remain at the site where they are injected. It is not yet clear whether this is due to improperly administered injections — which might be entering blood vessels rather than remaining intramuscular — or if the migration occurs no matter whether the injection is intravenous or not.
A team of German pathologists asked BioNTech (Pfizer) for information about the components of the company’s “vaccine”. They didn’t get much of an answer to their questions, but there is some interesting analysis in the report below.
Many thanks to Hellequin GB for translating this article from Report24:
BioNTech responds to pathologists: COVID vaccine does not remain in place
The safety concerns of the group of scientists around the pathologists Prof. Arne Burkhardt and Prof. Walter Lang regarding the Covid vaccine Comirnaty, which is most commonly administered in Germany, could not be dispelled by the manufacturer. The focus is also on the spike protein.
“Our pathologists asked important questions to BioNTech. These were not answered or were insufficiently answered in a letter dated February 16, 2022. The company has admitted that the vaccines do not remain at the injection site. BioNTech seems to have no idea how long the spike formation lasts or whether the lipid nanoparticles can fuse into larger units in the body. With regard to the amount of lipid nanoparticles, commercial secrecy interests are cited.”
This is the summary of the statement by Dr. Burkhardt and Dr. Lang on the response from the vaccine manufacturer, whom they contacted with detailed questions in early February. Report24.news reported:
In their intention to either reject or confirm a causal connection between the organ damage of the people they autopsied and the vaccine Comirnaty. Among other things, they wanted to find out how long the coding ability of the mRNA remains in the body and how quickly the components of the lipid nanoparticles are broken down. It has now been proven that the spike protein formed in the body as a result of vaccination against Covid-19 can be responsible for inflammation and lesions in vessels. The pathologists provided the relevant evidence a few weeks ago when they were able to reliably demonstrate the vaccine spike protein in the vessels of a person who died four months after their Covid vaccination and who had vascular lesions and vaccination-induced myocarditis.
Background information, more detailed explanations and all questions and answers from BioNTech can be found on the Pathology Conference website. The following is reproduced from it (emphasis and subheadings by editors):
Inoculum particle distribution studies: Injections detectable throughout the body
In the Comirnaty vaccination, modRNA packaged in lipid nanoparticles is injected into the body to induce the formation of the spike protein, i.e. a surface structure of coronaviruses. An immune response should then be triggered against this spike protein, which should protect against corona infections.
However, an immune response against spike proteins protruding on body cell surfaces can also lead to undesired side effects. Therefore, the distribution of Comirnaty in the body and its further processing is an important aspect of drug safety. Studies on the dissemination of drugs are usually a prerequisite for the approval of drugs.
Unfortunately, BioNTech did not answer the question as to which cells and tissues spike proteins are formed in. But in a later question reference was made to vaccine particle distribution studies in mice and rats which showed that these injections were detectable throughout the body. The seed particles do not remain at the injection site.
Fusion of lipid nanoparticles: neither reports in literature nor own attempts
The question of the duration of spike protein formation was not answered. In an older publication from 2014, the questioning scientists found information from BioNTech founder Ugur Sahin that after about ten days half of the injected dose of modified RNA, as used in Comirnaty, was degraded.
With a pot of water and a few drops of oil, you can watch small lipid droplets fuse into large ones. The scientists wanted to know whether similar problems could also be feared with lipid nanoparticles. BioNTech has not found any reports on this in the literature, but has not carried out any tests of its own. To prevent the fusion of lipid nanoparticles in the body, polyethylene glycol (PEG) was added, which is known to cause severe allergic reactions.
“Deimmunizing” modRNA format is used
There seems to be reasonably good information on the non-human lipid nanoparticle ingredients ALC-0159 and ALC-0315, for which BioNTech provided answers that the scientists asking the question didn’t even ask for.
However, BioNTech was unwilling to answer questions about the number of lipid nanoparticles in a Comirnaty dose. “We are unable to provide information on the number of lipid nanoparticles in a dose of Comirnaty or the difference between individual doses, as this is commercially sensitive information.”
From the answers concerning the modified RNA used, the questioning scientists conclude that a modRNA format is used, which BioNTech founder Ugur Sahin described as a “deimmunizing variant”.
Reutlingen, February 20th, 2022
Prof. Dr. Arne Burkhardt
Prof. Dr. Walter Lang